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African Americans (AAs) have lower circulating 25-hydroxyvitamin D3 [25(OH)D3] concen-
trations and higher prostate cancer (CaP) aggressiveness than other racial/ethnic groups.
The purpose of the current study was to examine the relationship between plasma 25(OH)
D3, African ancestry and CaP aggressiveness among AAs and European Americans
(EAs).
Methods
Plasma 25(OH)D3 was measured using LC-MS/MS (Liquid Chromatography Tandem
Mass Spectrometry) in 537 AA and 663 EA newly-diagnosed CaP patients from the North
Carolina-Louisiana Prostate Cancer Project (PCaP) classified as having either ‘high’ or
‘low’ aggressive disease based on clinical stage, Gleason grade and prostate specific anti-
gen at diagnosis. Mean plasma 25(OH)D3 concentrations were compared by proportion of
African ancestry. Logistic regression was used to calculate multivariable adjusted odds ra-
tios (OR) and 95% confidence intervals (95%CI) for high aggressive CaP by tertile of plas-
ma 25(OH)D3.
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Results
AAs with highest percent African ancestry (>95%) had the lowest mean plasma 25(OH)D3
concentrations. Overall, plasma 25(OH)D3 was associated positively with aggressiveness
among AA men, an association that was modified by calcium intake (ORT3vs.T1: 2.23, 95%
CI: 1.26–3.95 among men with low calcium intake, and ORT3vs.T1: 0.19, 95%CI: 0.05–0.70
among men with high calcium intake). Among EAs, the point estimates of the ORs were
<1.0 for the upper tertiles with CIs that included the null.
Conclusions
Among AAs, plasma 25(OH)D3 was associated positively with CaP aggressiveness among
men with low calcium intake and inversely among men with high calcium intake. The clinical
significance of circulating concentrations of 25(OH)D3 and interactions with calcium intake
in the AA population warrants further study.
Introduction
African Americans (AAs) are diagnosed with aggressive prostate cancer more often and have
more than twice the prostate cancer mortality rates as European Americans (EAs) [1,2]. Vita-
min D has been hypothesized to play a role in explaining some of the racial disparities in cancer
mortality for various cancer types [3–5]. Mean circulating 25-hydroxyvitamin D3 [25(OH)D3,
the metabolite measured to assess vitamin D status clinically] is lower among AAs than EAs
[5–9]. Vitamin D in humans is derived from cutaneous exposure to ultraviolet (UV)-B rays
from sunlight and the conversion of 7-dehydrocholesterol to pre-vitamin D3 with subsequent
hepatic and renal conversion of D3 to the most active metabolite 1,25-dihydroxyvitamin D3
[1,25(OH)2D3] [10]. Melanin blocks UV-B, and individuals with darker skin pigmentation re-
quire longer time in the sun to produce equivalent amounts of 25(OH)D3 than individuals
with less pigmented skin [11]. Dietary and supplemental intake contribute proportionally
much less to vitamin D status. Intake of vitamin D is lower in AAs than in EAs which may re-
flect{16 low intake of milk products among AAs due to a higher prevalence of lactose intoler-
ance [12–14]. African ancestry is inversely associated with serum 25(OH)D3 concentrations
[15] and somewhat correlated with skin pigmentation [16,17]. The proportion of African an-
cestry may be related to genetic differences that affect metabolism, activity or storage of vita-
min D.
The epidemiological evidence for an association between circulating 25(OH)D3 and pros-
tate cancer risk has been reviewed [18–20], though few studies have included a large enough
sample of AAs to examine intra-racial associations with circulating concentrations of vitamin
D [21,22]. The majority of studies have found either null or inverse associations [23–33], but
several studies have shown increased risk of prostate cancer at the highest concentrations of 25
(OH)D3 [34–38]. Other studies reported a U- or J-shaped association between 25(OH)D3 and
prostate cancer risk [39,40] or overall mortality [41,42]. A recent meta-analysis reported in-
verse associations with overall cancer mortality for supplementation trials of vitamin D3 but
not D2, and no substantial association between circulating 25(OH)D and prostate cancer-spe-
cific death [43]. Calcium and vitamin D levels are regulated homeostatically. An interaction be-
tween calcium intake and vitamin D status in relation to prostate cancer has been suggested,
but rarely reported [34,38].
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Given the higher incidence of aggressive prostate cancer among AAs, the conflicting evi-
dence for an association between 25(OH)D3 and prostate cancer, and the underrepresentation
of AA in previously published research, the goals of this study were to examine the association
between plasma 25(OH)D3 concentrations and prostate cancer aggressiveness in a large, popu-
lation-based, case-only study of AA and EA men newly diagnosed with prostate cancer, to ex-
amine potential interactions with calcium intake, and to examine if African ancestry as




This study utilizes data from a subset of research subjects in the North Carolina-Louisiana
Prostate Cancer Project (PCaP), a population-based, case-only study designed to address racial
disparities in prostate cancer. A subset of PCaP participants (n = 1200) who had agreed to fu-
ture use of their biologic specimens for research were selected a priori for inclusion in this
study due to resource constraints. The study set consisted of all research subjects diagnosed
with high aggressive prostate cancer (n = 302, see aggressiveness definition in Outcomes As-
sessment section), 112 research subjects diagnosed with Gleason score = 4+3 (all other inter-
mediate aggressive cancer research subjects were excluded), and a random subset (n = 786) of
research subjects diagnosed with low aggressive cancer (a random subset was selected because
there were many more low aggressive cancer cases than needed for analyses). This research
subject selection strategy was implemented prior to any 25(OH)D3 lab measurements or data
analyses. PCaP methods have been described in detail [44]. Briefly, residents of the North Ca-
rolina (NC) and Louisiana (LA) study areas between the ages of 40–79 years old with an initial
diagnosis of histologically-confirmed adenocarcinoma of the prostate between July 2004 and
July 2009 were eligible. The sampling frame was weighted to include all eligible AAs, and EAs
were under-sampled randomly using randomized recruitment (36). The PCaP protocol was ap-
proved by the institutional review boards at all participating sites, which included the two pa-
tient recruitment sites [the University of North Carolina at Chapel Hill (UNC) and Louisiana
State University Health Sciences Center (LSUHSC)], and the Department of Defense Prostate
Cancer Research Program. Prior to their participation in PCaP, all men signed an informed
consent and provided signed release for medical records and tumor specimens.
Data Collection
Research subjects were visited in their home by a trained registered nurse who conducted a
structured interview, performed anthropometric measurements, and collected biospecimens.
The majority of visits were completed on the average within four months of diagnosis. Struc-
tured questionnaires were used to collect information about lifestyle factors, family history of
prostate cancer, cancer screening history, and prescribed and over-the-counter medications
used in the prior two weeks, which included non-steroidal anti-inflammatory drugs (NSAIDs),
vitamins and supplements. Men were asked to report usual dietary intake in the year prior to
diagnosis using the National Cancer Institute Diet History Questionnaire (DHQ) modified to
capture foods common to the geographic areas (e.g., Cajun and creole foods). The modified
DHQ inquired about frequency of intake and usual portion size for 124 food items, and food
preparation methods. Questionnaire responses were linked to the DHQ Nutrient Database
through the DietCalc software, and intakes of macronutrients, micronutrients, and minerals,
including calcium, were computed. After the in-home visit, medical records and tumor tissue
samples were collected for each research subject who provided authorization for release.
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Vitamin D Assessment
During in-home visits, study nurses collected 6.5 ml of fasting venous blood into lavender top
(EDTA) tubes which were wrapped in foil and transported on ice at 4°C to the Blood and Tis-
sue Procurement Core Laboratory at LSU or the BioSpecimen Processing Facility at UNC. The
majority of PCaP blood samples were processed to serum, plasma and DNA on the same or the
following day and aliquoted and stored at -80°C. Plasma concentrations of 25(OH)D3 were de-
termined using LC-MS/MS at Heartland Assays, Inc. PCaP plasma samples were stored at
-80°C for up to eight years prior to measurement; concentrations of 25(OH)D3 in stored sam-
ples has been reported to be quite stable even at -20°C for up to ten years [45].
Ancestry Informative Markers
Ancestry informative markers were genotyped and ancestry estimates (i.e., proportion African
descent) were determined as described [46]. Allele frequencies were estimated using maximum
likelihood methods. Individual ancestry proportions for self-reporting AA and EA research
subjects were estimated using a Bayesian Markov Chain Monte Carlo (MCMC) clustering algo-
rithm implemented in STRUCTURE 2.3.1. Publicly available genotypes were included from
YRI, CEU and ASI ancestral populations in the STRUCTURE procedure.
Outcome Assessment
Extensive medical record abstraction was performed in PCaP and data on Gleason grade, clini-
cal stage, and prostate specific antigen (PSA) at diagnosis were used to classify research subjects
into three categories of aggressiveness as follows [44]: High aggressive cases: Gleason sum 8,
or PSA>20 ng/ml at diagnosis, or Gleason sum = 7 AND stage T3-T4; low aggressive cases:
Gleason sum<7 AND diagnosed at stage T1-T2 AND PSA<10 ng/ml at diagnosis; intermedi-
ate aggressive cases: all other cases. For the current study, all PCaP research subjects diagnosed
with high aggressive cancer and intermediate aggressive cancer research subjects who had
Gleason sum = 7 with primary Gleason pattern 4 were combined (this group is referred to as
‘high aggressive’). The high aggressive group was compared to a random sample of low aggres-
sive cases with Gleason sum<7, stage T1-T2, and PSA<9 ng/ml (as described in Study Popula-
tion above).
Statistical analysis
Research subjects were excluded who had incomplete data on confounders or effect modifiers
(40 total exclusions). The final study sample consisted of 519 AA and 641 EA men. Descriptive
analyses included calculating means and standard deviations for continuous variables and fre-
quencies and percentages for categorical variables, which included frequencies by predeter-
mined categories of 25(OH)D3 based on previous literature (<20ng/ml, 20–30ng/ml, and
30ng/ml) and by tertiles based on the 25(OH)D3 race-specific (self-reported race) distribu-
tions in PCaP. Means and standard deviations of plasma 25(OH)D3 were calculated for EAs
and AAs, and by African ancestry, categorized as>95%, 85–95%,<85% based on ancestry
informative markers to be comparable to previous literature [15]. Crude and multivariable lo-
gistic regressions were used to examine the relationships between plasma 25(OH)D3 concen-
trations and prostate cancer aggressiveness by comparing high aggressive research subjects to
low aggressive research subjects. The distributions of plasma 25(OH)D3 were different between
AAs and EAs, so all analyses were stratified by race and plasma 25(OH)D3 concentrations
were grouped into tertiles (T) with race-specific cut-off points based on the distribution
among low aggressive prostate cancer cases; for AAs: T1<13.30, 13.30 T2< 18.90,
Vitamin D, Ancestry, and Aggressive Prostate Cancer
PLOS ONE | DOI:10.1371/journal.pone.0125151 April 28, 2015 4 / 15
T318.90ng/ml; and for EAs: T1<21.14, 21.14 T2< 26.67, T326.67 ng/ml. The lowest
race-specific tertile was used as the referent in race-stratified analyses. Confounding was as-
sessed using the 10% rule. Final multivariable logistic regression models adjusted for age
(years, continuous); African ancestry (%, continuous); body mass index (BMI; kg/m2, continu-
ous); education (less than 8th grade or some high school; high school graduate or vocational/
technical school; some college or college graduate; some graduate training or graduate/profes-
sional degree); PSA screening history (0, 1–7,>7 screenings); smoking (non-smoker, former
smoker, and current smoker); alcohol intake (g/day, continuous); NSAID use (yes/no); study
site (NC, LA); season of blood draw (winter, spring, summer, and fall); physical activity (MET-
hrs/wk, continuous); and total energy intake (kcal/day, continuous). Based on 10% rule, marital
status and family history of first degree relative with prostate cancer were not confounders and
were not included in the final model. Stratified analyses were performed to explore possible ef-
fect modifying role of age (< 65, 65 years), BMI (< 30,30 kg/m2), study site (NC, LA), and
dietary calcium intake (< 1200, 1200 mg/d) in the relationships between plasma 25(OH)D3
concentrations and prostate cancer aggressiveness, and interactions were tested by including
an interaction term in fully adjusted race-stratified models. Sensitivity analyses were performed
to examine effects of recent weight change (measured weight at time of interview minus self-re-
port weight one year prior to diagnosis), number of days until processing of blood sample (0–1
day compared to2 days; 10% were processed2 days), or current use of vitamin D supple-
ments at time of blood draw. In addition, research subjects with Gleason score = 4+3 (included
in the high risk group in this study, but classified as intermediate aggressive by PCaP) were ex-
cluded in sensitivity analyses to restrict the high aggressive group to those subjects with Glea-
son score of 8 or greater in order to evaluate whether including less aggressive cancers in the
high aggressive group may have biased the associations observed. SAS version 9.3 (SAS Insti-
tute, Cary, NC) was used for all analyses, and statistical significance was evaluated at p<0.05
(two-tailed).
Results
Data from 306 AAs and 456 EAs with low aggressive prostate cancer, and 213 AAs and 185
EAs with high aggressive prostate cancer were included in the analyses. The majority of PCaP
research subjects had no family history of prostate cancer, were former smokers, were married
or living with a partner, and were not taking vitamin D supplements at the time of interview
(Table 1). Almost half of interviews occurred during the Fall (September 21 to December 20).
Average age of research subjects was 63 years and average BMI was 29.3 kg/m2. Low and high
aggressive cases were distributed similarly at the NC and LA study sites
The majority of AAs (67% of high aggressive and 70% of low aggressive cases) had 25(OH)
D3 concentrations below 20ng/ml, compared to approximately 30% of EAs (31% of high ag-
gressive and 28% of low aggressive) (Fig 1). Research subjects with higher proportions of Afri-
can ancestry, as indicated by ancestry informative genetic markers, had lower mean
concentrations of plasma 25(OH)D3 (17.0 ± 7.2, 18.4 ± 8.3, and 19.1 ± 7.6 ng/ml for AAs
with African ancestry of>95%, 85–95%, and<85%, respectively), whereas the mean concen-
tration of 25(OH)D3 among self declared EA men (all with<40% African ancestry) was
24.6 ± 9.7 ng/ml.
Among AAs, higher odds of high aggressive prostate cancer were observed for research sub-
jects in the second and third tertiles of 25(OH)D3 concentration compared to the first, after ad-
justment for potential confounders (ORT2 vs T1: 1.80, 95%CI: 1.10–2.96 and ORT3 vs. T1: 1.46,
95%CI: 0.89–2.39, Table 2). In contrast, the point estimates of the ORs for EAs were less than
1.0 but not statistically significantly different from 1.0 (ORT2 vs T1: 0.92, 95%CI: 0.59–1.43 and
Vitamin D, Ancestry, and Aggressive Prostate Cancer
PLOS ONE | DOI:10.1371/journal.pone.0125151 April 28, 2015 5 / 15
Table 1. Descriptive statistics by prostate cancer aggressiveness and race.
Characteristics Low Aggressive High Aggressive
AA EA AA EA
Continuous variables Mean SD Mean SD Mean SD Mean SD
Age, yrs 61 8 63 7 62 8 66 8
Body mass index, kg/m2 28.8 5.3 29.0 4.8 29.4 6.6 29.8 5.0
Total energy intake, kcal/day 2638.2 1334.3 2355.0 1155.1 3033.0 1607.2 2504.2 1269.6
Alcohol intake, g/day 17.3 45.1 14.3 43.2 20.0 63.0 19.3 49.4
Total vitamin D intake, mcg/d 6.3 7.1 7.7 8.0 7.2 18.9 8.8 9.3
Calcium intake, mg/d 804.3 471.4 923.9 488.4 929.1 516.4 1020.4 585.3
Physical activity, MET-hours/week 3.6 5.1 4.3 5.5 3.3 5.0 4.2 5.6
Plasma 25(OH)D3, ng/ml 17.1 7.4 24.5 8.6 18.4 7.7 25.0 12.0
Categorical variables n % n % n % n %
Study Site
NC 151 49.4 223 51.1 101 47.4 87 47.0
LA 155 50.6 233 48.9 112 52.6 98 53.0
Family History of Prostate Cancer
No affected 1st degree relative 196 69.5 323 72.9 146 73.4 143 75.7
At least 1 affected 1st degree relative 86 30.5 120 27.1 53 26.6 33 18.7
Education
Grad/professional degree 24 7.8 98 21.5 7 3.3 41 22.2
Some college or college graduate 95 31.1 189 41.5 60 28.2 77 41.6
High school grad or voc/tech school 107 35.0 136 29.8 68 31.9 41 22.2
Less than high school education 80 26.1 33 7.2 78 36.6 26 14.0
PSA Screening History
0 screenings 96 31.4 69 15.1 115 54.0 33 17.8
1–7 screenings 137 44.8 206 45.2 60 28.2 79 42.7
> 7 screenings 73 23.8 181 39.7 38 17.8 73 39.5
Smoking Status
Current smokers 114 37.3 179 39.3 44 20.7 69 37.3
Former smokers 131 42.8 240 52.6 117 54.9 97 52.4
Non-smokers 61 19.9 37 8.1 52 24.4 19 10.3
NSAID Use
No 147 48.0 150 31.6 82 38.5 65 35.1
Yes 159 52.0 323 68.4 131 61.5 120 64.9
Taking dietary supplement containing vitamin D at the time of the interview
No 253 81.9 312 70.0 173 79.4 118 63.1
Yes 56 18.1 144 30.0 45 20.6 69 26.9
Season
Winter (21Dec–22Mar) 55 18.0 81 17.7 26 12.2 31 16.8
Spring (21Mar–20Jun) 54 17.6 88 19.3 46 21.6 35 18.9
Summer (21Jun–20Sep) 53 17.3 71 15.6 34 16.0 32 17.3
Fall (21Sep–20Dec) 144 47.1 216 47.4 107 50.2 87 47.0
African Ancestry (among African Americans)
High (>0.95) 197 64.4 NA NA 132 62.0 NA NA
Medium (0.85–<0.95) 49 16.0 NA NA 35 16.4 NA NA
Low (<0.85) 60 19.6 NA NA 46 21.6 NA NA
Marital Status
(Continued)
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ORT3 vs. T1: 0.92, 95%CI: 0.58–1.44). The associations between 25(OH)D3 and prostate cancer
aggressiveness were not modified by age, BMI, or study site (Table 3). However, dietary calci-
um intake appeared to modify the association among AAs (Pinteraction = 0.001). High aggressive
prostate cancer was associated with higher 25(OH)D3 concentrations among men with low
calcium intake (<1200mg/d; ORT3 vs. T1: 2.23, 95%CI: 1.26–3.95). A decreased odds of high ag-
gressive prostate cancer for higher 25(OH)D3 was observed among men with higher calcium
intake ( 1200 mg/d; ORT3 vs. T1: 0.19, 95%CI: 0.05–0.70). The interaction p-value for EAs was
not significant (p = 0.99), though the effect estimates were in a similar direction as those of
AAs in men with higher calcium intake.
Table 1. (Continued)
Characteristics Low Aggressive High Aggressive
AA EA AA EA
Continuous variables Mean SD Mean SD Mean SD Mean SD
Single/separated/divorced/widowed 95 31.1 59 12.9 74 34.7 39 21.1
Married/living with partner 211 68.9 397 87.1 139 65.3 146 78.9
doi:10.1371/journal.pone.0125151.t001
Fig 1. Distribution of plasma 25(OH)D3 by prostate cancer aggressiveness and race.
doi:10.1371/journal.pone.0125151.g001
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In sensitivity analyses, a variable for recent weight change [measured weight in kilograms
(kg) at time of interview minus self-reported weight one year prior to diagnosis in kg converted
from pounds (lbs)] was included in the models, and there was no substantial change (i.e.,
>10% change in effect estimates) in the results. Adjusting for number of days to processing the
blood sample (blood samples from 126 men were processed two days after collection and from
one man five days after collection, whereas all others were processed on the same or next day
after collection, with the majority, n = 650 processed on the same day) did not affect the results,
neither did adjusting for vitamin D supplement use at the time of the interview. The OR for
AA men in the highest tertile of 25(OH)D3 compared to the lowest strengthened to 1.76 (95%
CI: 1.02–3.05) after excluding those research subjects withtwo days between collection and
processing. Excluding men who reported taking a vitamin D supplement at the time of inter-
view (19% of AAs and 32% of EAs) or excluding men with Gleason score = 4+3 (originally clas-
sified by PCaP as intermediate aggressive) did not change the results of these analyses.
Discussion
This population-based case-only study of AA and EA men with incident prostate cancer con-
firms the inverse relationship between African ancestry and circulating vitamin D concentra-
tions. A novel finding is that higher total plasma 25(OH)D3 concentrations were associated
with increased odds of high aggressive prostate cancer among AAs. This contrasts with the
findings among EAs where point estimates suggested a modest protective effect of higher con-
centrations which was not statistically significant after adjustment for potential confounders.
Associations were not modified by age, BMI, or study site. However, a significant interaction
between self-reported calcium intake and measured plasma 25(OH)D3 concentration was ob-
served among AAs. The positive association between 25(OH)D3 concentration and high ag-
gressive prostate cancer was observed in men with lower calcium intake (<1200mg/d),
whereas higher 25(OH)D3 was associated with reduced odds of high aggressive prostate cancer
among men with higher calcium intake (1200mg/d).
Similar to previous studies [15,47], mean concentrations of circulating 25(OH)D3 varied by
proportion of African ancestry; the lowest mean concentration occurred in men with>95%
African ancestry. The distribution of plasma 25(OH)D3 concentration differed between AAs
and EAs; race-specific cutpoints had to be used to ensure ample numbers of research subjects
in each category and to produce meaningful results when stratified by race. Approximately





















< 13.30 56/102 1.00 referent 1.00 referent
13.30  T2 < 18.90 76/100 1.40 0.89, 2.18 1.80 1.10, 2.96
 18.90 81/104 1.36 0.88, 2.11 1.46 0.89, 2.39 0.27
European
Americans
< 21.14 67/155 1.00 referent 1.00 referent
21.14  T2 < 26.67 58/150 0.90 0.59, 1.37 0.92 0.59, 1.43
 26.67 60/151 0.88 0.58, 1.34 0.92 0.58, 1.44 0.71
aAdjusted for age, African ancestry, BMI, total energy intake, alcohol intake, physical activity, smoking status, educational status, PSA screening history,
study site, NSAIDs use, and season of blood draw
doi:10.1371/journal.pone.0125151.t002
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Table 3. Association betweenmeasured concentrations of plasma 25(OH)D3 and prostate cancer aggressiveness stratified by race and selected
demographic, clinical and dietary characteristics.
Race Characteristic Tertilesa Pinteraction
1 2 3
Age, years
African Americans < 65
High aggressive/ low aggressive, n 35/65 47/75 44/67
OR (95% CI) b 1.00 (Ref.) 1.70 (0.90–3.19) 1.52 (0.80–2.86)
 65
High aggressive/ low aggressive, n 21/37 29/25 37/37
OR (95% CI) b 1.00 (Ref.) 2.42 (0.97–6.06) 1.72 (0.70–4.22) 0.82
European Americans < 65
High aggressive/ low aggressive, n 28/91 23/87 23/83
OR (95% CI) b 1.00 (Ref.) 0.85 (0.44–1.65) 0.97 (0.49–1.93)
 65
High aggressive/ low aggressive, n 39/64 35/63 37/68
OR (95% CI) b 1.00 (Ref.) 0.89 (0.49–1.64) 0.83 (0.44–1.55) 0.91
BMI (kg/m2)
African Americans < 30
High aggressive/ low aggressive, n 33/65 43/57 57/74
OR (95% CI) c 1.00 (Ref.) 1.87 (0.96–3.65) 1.52 (0.80–2.88)
 30
High aggressive/ low aggressive, n 23/37 33/43 24/30
OR (95% CI) c 1.00 (Ref.) 1.71 (0.77–3.84) 1.05 (0.43–2.56) 0.78
European Americans < 30
High aggressive/ low aggressive, n 28/93 37/104 39/103
OR (95% CI) c 1.00 (Ref.) 1.19 (0.64–2.19) 1.20 (0.65–2.22)
 30
High aggressive/ low aggressive, n 39/62 21/46 21/48
OR (95% CI) c 1.00 (Ref.) 0.77 (0.38–1.58) 0.65 (0.31–1.36) 0.25
Study Site
African Americans LA
High aggressive/ low aggressive, n 22/46 40/49 50/60
OR (95% CI) d 1.00 (Ref.) 2.18 (1.00–4.75) 1.77 (0.83–3.78)
NC
High aggressive/ low aggressive, n 34/56 36/51 31/44
OR (95% CI) d 1.00 (Ref.) 1.58 (0.80–3.12) 1.33 (0.66–2.68) 0.78
European Americans LA
High aggressive/ low aggressive, n 35/71 28/82 35/80
OR (95% CI) d 1.0 (Ref.) 0.67 (0.35–1.27) 0.81 (0.43–1.54)
NC
High aggressive/ low aggressive, n 32/84 30/68 25/71
OR (95% CI) d 1.00 (Ref.) 1.16 (0.60–2.21) 1.02 (0.51–2.03) 0.57
Dietary Calcium Intake, mg/d
African Americans <1200
High aggressive/ low aggressive, n 39/92 59/87 63/75
OR (95% CI) e 1.00 (Ref.) 2.07 (1.17–3.66) 2.23 (1.26–3.95)
 1200
High aggressive/ low aggressive, n 17/10 17/13 18/29
OR (95% CI) e 1.00 (Ref.) 1.06 (0.28–3.99) 0.19 (0.05–0.70) 0.001
(Continued)
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70% of AA prostate cancer cases but only approximately 30% of EA cases had 25(OH)D3 con-
centrations<20ng/ml. While the distribution of African ancestry was not substantially differ-
ent between NC and LA in this PCaP subset, a higher percentage of AAs from NC versus LA
had 25(OH)D3 concentrations<20 ng/ml (74% versus 64%, respectively), which may reflect
variations in sunlight exposure and diet between research subjects from the two states.
The findings of increased odds of high aggressive prostate cancer at higher plasma 25(OH)
D3 concentrations among AAs is counter to the original hypothesis that higher vitamin D may
be protective against aggressive prostate cancer and contrasted to some epidemiological studies
supporting the original hypothesis [21,22,30,48,49]. However, several nested case-control stud-
ies have reported increased risk of aggressive prostate cancer [34,38] or total prostate cancer
[35,37] for men with higher concentrations of 25(OH)D3. The majority of these studies were
in European or EA populations (or did not report results separately by race), with 25(OH)D3
concentrations greater than approximately 32ng/ml associated with increased risk. These con-
centrations are much higher than those observed in PCaP AA research subjects at higher odds
of aggressive prostate cancer (second tertile cutpoint>13.3 ng/ml). The differences in study
populations, choice of control groups, and distribution of plasma 25(OH)D3 concentrations
limit ability to compare results across studies. Only 5% of AAs had 25(OH)D3 concentrations
above 32ng/ml in PCaP. Thus, it is unclear what the effect of higher concentrations of 25(OH)
D3 would be in this population.
In contrast with our findings, Murphy et al. reported that AA (and EA) men with low
serum 25(OH)D concentrations (<12 ng/ml compared to>12ng/ml) had higher odds of
higher Gleason grade and higher tumor stage in a cross-sectional study performed in Chicago,
IL [21]. Kristal et al. recently reported reduced risk of Gleason 7–10 prostate cancer among
AAs in the upper three quintiles of serum 25(OH)D compared to the lower two quintiles in the
Selenium and Vitamin E Cancer Prevention Trial [22]. In a recent randomized, placebo-con-
trolled clinical trial, varying doses of vitamin D supplementation had no effect on PSA levels in
healthy AA men without prostate cancer [50]. The current study results, along with these
Table 3. (Continued)
Race Characteristic Tertilesa Pinteraction
1 2 3
European Americans < 1200
High aggressive/ low aggressive, n 51/126 42/117 38/108
OR (95% CI) e 1.00 (Ref.) 0.97 (0.58–1.64) 0.97 (0.56–1.69)
 1200
High aggressive/ low aggressive, n 16/29 16/33 22/43
OR (95% CI) e 1.0 (Ref.) 0.77 (0.29–2.04) 0.87 (0.35–2.17) 0.99
a Cutpoints for tertiles of 25(OH)D3 for African Americans: T1<13.30, 13.30  T2 < 18.90, T3 18.90 ng/ml; for European Americans: T1<21.14,
21.14  T2 < 26.67, T3 26.67 ng/ml
b Adjusted for African ancestry, BMI, total energy intake, alcohol intake, physical activity, smoking status, educational status, PSA screening history, study
site, NSAIDs use, and season of blood draw
cAdjusted for age, African ancestry, total energy intake, alcohol intake, physical activity, smoking status, educational status, PSA screening history, study
site, NSAIDs use, and season of blood draw
dAdjusted for age, African ancestry, BMI, total energy intake, alcohol intake, physical activity, smoking status, educational status, PSA screening history,
NSAIDs use, and season of blood draw
eAdjusted for age, African ancestry, BMI, total energy intake, alcohol intake, physical activity, smoking status, educational status, PSA screening history,
study site, NSAIDs use, and season of blood draw
doi:10.1371/journal.pone.0125151.t003
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recent reports underscore the need for more research on vitamin D and prostate health among
AAs who have been underrepresented in previous research studies.
Experimental models support a role of vitamin D in halting prostate cancer progression
which contrasts with inconsistent findings in the epidemiologic literature. Vitamin D has been
reported to inhibit proliferation in prostate cancer cell lines and inhibit invasion and metasta-
ses in some prostate cancer animal models, such as the Dunning rat model [51–55]. The bal-
ance of 25(OH)D3 concentrations and 24-hydroxylation that inactivates 1,25(OH)2D3 at the
target tissue may affect the response to circulating 25(OH)D3 [39]. Clinical cutpoints for as-
sessing vitamin D status remain unstandardized, but the Institute of Medicine recommended a
25(OH)D3 cutpoint of>20ng/ml as sufficient for skeletal health outcomes [56]. Recent re-
search calls into question the uniform application of cutpoints across all racial groups [57].
The majority of 25(OH)D3 is bound to vitamin D binding protein in circulation [58]. Geno-
types of the gene encoding the vitamin D binding protein (GC) are distributed differentially
across races; AAs have a higher prevalence of genotypes associated with low levels of vitamin D
binding protein [59–62]. A recent study reported that AAs and EAs had similar concentrations
of free 25(OH)D [considered to be more bioavailable than bound 25(OH)D], after GC geno-
types were accounted for, which may explain the paradox of higher bone mineral density
among AAs than EAs even in the presence of lower total 25(OH)D concentrations [57]. Levels
of vitamin D binding protein were not available in the current study, though genotyping of
genes involved in vitamin D metabolism and activity (including the vitamin D binding protein,
GC) are underway.
Plasma samples were collected after diagnosis, so reverse causality is a possible explanation
for the findings; disease status may have affected plasma 25(OH)D3 concentrations. Vitamin
D is fat-soluble and stored in adipose tissue. One possible explanation for the unexpected find-
ings may be that men with high aggressive disease were more likely to have lost weight recently
than those with low aggressive disease, which would release 25(OH)D3 into circulation from
adipose tissue and increase plasma concentrations of 25(OH)D3. However, adjustment for re-
cent weight change in the year prior to diagnosis did not change the association between 25
(OH)D3 concentrations and aggressiveness. Systematic differences in the way blood samples
were collected and processed were investigated, but adjustment for time to blood processing
and exclusion of those research subjects with two or five days before processing also did not
substantially affect results. Another potential explanation for the unexpected finding was the
possibility that research subjects diagnosed with prostate cancer may have started supplemen-
tation with vitamin D after diagnosis but before the interview, and that this would have been
done differentially by AA research subjects with high versus low aggressive prostate cancer ei-
ther due to physician recommendation or of their own volition. Nurse interviewers conducted
an inventory of all medications and supplements used by research subjects at the time of the
home visit. A slightly higher percentage of AA men with high versus low aggressive prostate
cancer reported taking vitamin D supplements (21% versus 18%, respectively), but adjustment
for recent use of vitamin D supplements or exclusion of those subjects reporting vitamin D
supplement use did not change the results.
The current study found an interaction between calcium intake and plasma 25(OH)D3 con-
centrations among AAs. The positive association between 25(OH)D3 and high aggressive pros-
tate cancer was observed in men with low calcium intakes (below the Recommended Daily
Allowance of 1200 mg/d for men 71 years and older), whereas reduced odds of high aggressive
prostate cancer for high concentrations of 25(OH)D3 was observed among AA men with
higher calcium intakes. These results contrast with the Albanes et al. report of the Alpha-to-
copherol, Beta-carotene Cancer Prevention Study in Finnish men that increased risk of pros-
tate cancer for higher concentrations of serum 25(OH)D was more prominent among men
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with higher intakes of calcium (1338 mg/d) [38]. The Prostate, Lung, Colorectal and Ovarian
Cancer Screening Trial reported no difference in effect of 25(OH)D3 on prostate cancer across
all levels of calcium intake [34]. It is not clear if the finding in PCaP of an interaction with calci-
um represents a true biologic interaction perhaps related to genetic predisposition to lactose in-
tolerance or may be due to chance given the small number of research subjects with calcium
intake1200 mg/d. Further research should evaluate the interaction between calcium and vita-
min D in prostate cancer.
Strengths of the study include the use of rapid case ascertainment in identification of a pop-
ulation-based sample of a large number of clinically and epidemiologically well-characterized
AA and EA men with incident prostate cancer from two study sites in the United States. Addi-
tionally, all men were genotyped for ancestry informative markers and thus proportion of Afri-
can ancestry was available and used to reduce confounding by population stratification.
Sunlight exposure produces as much as 90% of the vitamin D requirement for humans [63].
Plasma concentrations as the exposure variable provide a better indicator of vitamin D status
than dietary intake or supplement data alone. Plasma 25(OH)D3 concentrations can vary by
season, so season of blood collection was controlled for in the analyses. Nutrient biomarkers,
such as plasma 25(OH)D3, provide more objective markers of exposure than participant recall
of diet and supplement use. However, one measurement of plasma reflects only recent expo-
sure, though 25(OH)D3 concentrations and skin color, the major determinant of 25(OH)D3,
are relatively stable over time [28,64]. Other limitations of this study include those inherent to
any observational epidemiological investigation, such as non-participation and the possibility
of selection bias or recall bias for self-reported covariates.
In conclusion, an interaction between plasma concentrations of 25(OH)D3 and calcium in-
take was observed in relation to odds of high aggressive prostate cancer among AAs but not
EAs. The study results add to the growing literature [22,40] suggesting that the relationship be-
tween 25(OH)D3 and disease is complex particularly in the context of cancer-related racial dis-
parities. Recommendations for universal cutpoints of vitamin D status and increasing 25(OH)
D3 concentrations in all populations may not be ideal. Other factors may need to be considered
which include calcium intake, genetic ancestry, background variation, and concentrations of
bioavailable vitamin D.
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